REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Anti-idiotypic Anti-idiotypicAnti-idiotypic patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/16/07 - 20070190045 - Anti-cd3 and antigen-specific immunotherapy to treat autoimmunity The invention provides methods for treating autoimmunity and for reestablishing tolerance. The methods involve the coadministration of anti-CD3 antibodies and self-antigens. The coadministration has the potential to provide a synergistic effect of protecting or reducing autoaggressive immune processes and/or of reestablishing tolerance towards self-antigens. An underlying rationale behind the methods ... 08/16/07 - 20070190044 - Compositions and methods for manipulating levels of antigen-specific antibodies in a mammal The invention provides compositions and methods for increasing the levels of an autoantigen-specific IgM antibody in a mammal and, thus, decreasing the levels of a circulating autoantigen in a mammal. Using these autoantigen-specific IgM anti-bodies, the invention provides compositions and methods for ameliorating an autoimmune disease in a mammal. In ... 08/02/07 - 20070178083 - Medicinal compositions containing fc receptor gamma-chain activator The present invention provides pharmaceutical compositions composing, as an active ingredient, a substance capable of activating the γ chain of Fc receptors (FcRγ) (provided that the substance is not an immunoglobulin for intravenous injection), and agents for stimulating myelinogenesis. The invention also provides agents for stimulating the differentiation of oligodendroglial ... 08/02/07 - 20070178082 - Stabilized single domain antibodies The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods ... 07/12/07 - 20070160595 - Human tumor necrosis factor tr20 and methods based thereon The present invention relates to TR20 polypeptides. In particular, isolated nucleic acid molecules are provided encoding human TR20 protein. TR20 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR20 ... 06/28/07 - 20070148163 - Mutants of anti-cd40 antibody A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-CD40 antibody, comprising mutation and/or substitution of at least one amino acid in the constant region to reduce the ... 06/28/07 - 20070148162 - Molecule which binds cd80 and cd86 The present invention relates to the identification of molecules, which are specific to CD80 and CD86 antigens. Also preferably, such antibodies are capable of inhibiting the binding of CD28 and CTLA4 to those receptors. Those molecules are able to inhibit T cell mediated immune reactions. ... 06/21/07 - 20070141047 - Feline immunoglobulin e proteins and compositions thereof The invention relates to: nucleic acid molecules encoding the light chain and heavy chain of feline immunoglobulin E (IgE), including species-specific regions of feline IgE; proteins encoded by the nucleic acid molecules; inhibitors to the nucleic acids and proteins; antibodies to the proteins; cells transformed with the nucleic acid molecules; ... 05/17/07 - 20070110742 - Recombinant peptide vector comprising the gene for treatment for autoimmune diseases The present invention provides a recombinant peptide vector comprising a leader peptide, linker DNAs and a DNA construct formed by operably linking expression control sequences with a therapeutic gene encoding a fusion protein where the extracellular domain of CTLA4 is bound to the Fc fragment of immunoglobulin, wherein the leader ... 04/19/07 - 20070086995 - Methods of treating ige-mediated disorders comprising the administration of high concentration anti-ige antibody formulations The present application relates to methods of treating IgE-mediated disorders comprising the administration of highly concentrated anti-IgE antibody formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. ... 04/19/07 - 20070086994 - Anti-nik antibodies and uses thereof An antibody or antibody preparation being capable of specifically binding the amino acid sequence of NF-&kgr;B-inducing kinase (NIK) MAP3K14, or a specific portion thereof, and of thereby regulating a biochemical activity of NIK, and/or enabling detection of NIK or a specific portion thereof. ... 04/12/07 - 20070081989 - Treatment of b cell diseases using anti-germline antibody binding agents Methods for reducing the number of pathologic antibody producing B cells in a patient suffering from an autoimmune disease by administration of an anti-germline antibody are described. Methods for removing pathologic antibodies and B cells and plasma cells producing pathologic antibodies from the body of a patient suffering from autoimmune ... 03/29/07 - 20070071743 - Novel human cell surface protein with immunoglobulin folds, bgs-19 The present invention provides novel polynucleotides encoding BGS-19 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying the novel BGS-19 polypeptides to the diagnosis, treatment, and/or prevention ... 03/22/07 - 20070065425 - Anti-idiotypic antibody neutralizing the inhibitor activity of a factor viii inhibitor antibody The present invention is related to a monoclonal anti-idiotypic antibody directed against a Factor VIII inhibitor antibody binding to the domain A2 of Factor VIII, and to a cell line producing this monoclonal anti-idiotypic antibody, to the use of this monoclonal anti-idiotypic antibody as drug, and more particularly, to its ... 03/08/07 - 20070053900 - High concentration antibody and protein formulations The present application relates to highly concentrated antibody and protein formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. The application further describes articles of manufacture containing such formulations and method for using them to treat disorders ... 03/01/07 - 20070048298 - Method for treating autoimmune diseases and screening method for preventive or therapeutic agent for the same The present invention is directed to a method for treating autoimmune diseases comprising administering RBAp48 production suppressor or inhibitor; a screening method for a preventive or therapeutic agent for autoimmune diseases comprising determining RBAp48 production suppressing effect or inhibitory effect of a sample; a diagnosis agent or a diagnosing kit ... 02/22/07 - 20070041966 - Polypeptides including modified constant regions Disclosed are processes for producing a variant polypeptide (e.g. antibodies) having increased binding affinity for an FcγR, which processes comprise modifying the polypeptides by substitution of the amino acid at position 268 of a human IgG CH2 region for a non-native polar or charged amino acid e.g. Gin, Asn, Glu, ... 02/22/07 - 20070041965 - Novel dermatophagoides nucleic acid molecules, proteins and uses thereof The present invention relates to high molecular weight Dermatophagoides proteins, nucleic acid molecules encoding such proteins, and therapeutic and diagnostic reagents derived from such proteins. ... 02/22/07 - 20070041964 - Wisp polypeptides and nucleic acids encoding same Wnt-1-Induced Secreted Proteins (WISPs) are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to ... 01/25/07 - 20070020256 - Methods for treatment of allergic asthma Methods of treatment of allergic asthma with IgE antagonists, including anti-IgE antibodies, IgE variants, peptide antagonists, peptidomimetics and other small molecules, are described. ... 01/18/07 - 20070014785 - Use of antibodies against cd20 for the treatment of the graft versus host disease It is described the use of antibodies against exogenous surface antigens not present on normal human T lymphocytes for the preparation of compositions for the treatment of the graft versus host disease in patients who have received T lymphocytes transduced with such exogenous surface antigens. ... 01/11/07 - 20070009507 - Fibrin citrulline derivatives and their use for diagnosing or treating rheumatoid arthritis The invention concerns citrulline polypeptide derived from fibrin useful for diagnosing or treating rheumatoid arthritis. ... 01/04/07 - 20070003544 - Combination therapy for treatment of autoimmune diseases using b- cell depleting/immunoregulatory antibody combination The present invention concerns treatment of autoimmune diseases with the combination of an immunoregulatory antibody, e.g. an anti-B7.1 or anti-B7.2 or anti-CD40L antibody and at least one B cell depleting antibody, such as CD19, CD20, CD22, CD23, or CD37, wherein such antibodies may be administered separately, or in combination, and ... 01/04/07 - 20070003543 - Low dose histone peptide treatment for autoimmune disorders The present invention provides low dose compositions comprising peptides and methods of using the same to treat autoimmune disorders, such as lupus. In particular, the present invention provides low dose compositions comprising nucleosomal histone peptide autoepitopes comprising MHC class I and II binding motifs and methods of using the same ... 01/04/07 - 20070003542 - Methods for treating diseases or conditions with peptide constructs This invention relates to peptides directing a CD4 related T helper cell response wherein the peptides may be used as an adjuvant provided with an antigen or as an immunomodulatory agent without an antigen and compositions comprising modification of a fifteen-mer peptide sequence from the MHC IIβ chain at positions ... 12/28/06 - 20060292138 - Allergen vaccine proteins for the treatment and prevention of allergic diseases The present invention provides fusion proteins comprising an allergen sequence linked via an IgG hinge region to another polypeptide sequence capable of specifically binding to a native IgG inhibitory receptor containing an immune receptor tyrosine based inhibitory motif (ITIM). They are designed to cross-link an Fc receptor for IgE (e.g., ... 12/21/06 - 20060286090 - Mediators of epithelial adhesion and their role in cancer and skin disorders Perp is shown to mediate stratified epithelial development in vivo. Perp localizes specifically to desmosomes, adhesion junctions important for tissue integrity. In some embodiments of the invention, detection of autoantibodies specific for perp find use in the diagnosis of pemphigus. In other embodiments, agent that upregulate or mimic perp function ... 12/21/06 - 20060286089 - Compositions and methods for the treatment of burns and sepsis The present invention relates generally to methods for treating burns and sepsis, in particular for treating immune dysfunction associated with burns and sepsis. The present invention also relates to activating and expanding T cells for the treatment of burns and sepsis. ... 12/14/06 - 20060280732 - Peptides modulating caspase activation The present invention provides structures of small molecules capable of modulating apoptotic cell death. More specifically, the structures relate to the structures of apoptotic active sites of mammalian alpha-fetoprotein (AFP) and albumin. Peptides mimicking the active site contain two sequences, Arg-Gly-Asp and Asp-X-X-Asp, wherein X means any amino acid. These ... 12/07/06 - 20060275284 - Combination therapy for treatment of autoimmune diseases using b-cell depleting/immunoregulatory antibody combination The present invention concerns treatment of autoimmune diseases with the combination of an immunoregulatory antibody, e.g. an anti-B7.1 or anti-B7.2 or anti-CD40L antibody and at least one B cell depleting antibody, such as CD19, CD20, CD22, CD23, or CD37, wherein such antibodies may be administered separately, or in combination, and ... 11/23/06 - 20060263350 - Combination antihistamine medication The invention provides a topical pharmaceutical composition for application to the nasal or ocular mucosa which comprises (1) a pharmaceutical excipient suitable for topical administration, (2) a mucosal adjuvant, (3) an antihistamine drug and (4) a mast cell stabilizer, a non-steroidal anti-inflammatory drug, a phosphodiesterase inhibitor, an anti-IgE agent, heparin, ... 11/23/06 - 20060263349 - Pretreatment of a biological sample from an autoimmune disease subject The present application describes a method for pretreating a biological sample from an autoimmune disease subject in order to avoid interference, especially where the sample is to be subjected to a cell-based biological activity assay, such as a neutralizing antibody assay. ... 11/23/06 - 20060263348 - Apolipoprotein l-i and/or derivated polypeptide for the treatment of and/or the prevention of diseases induced by trypanosoma The present invention is related to a composition comprising apolipoprotein L-1, the use of apolipoprotein L-1 or a derivated polypeptide for the diagnostic, the treatment and/or the prevention of diseases induced in mammals by Trypanosoma. Another aspect is related to a transgenic non-human mammal comprising a polynucleotide expressing the apolipoprotein ... 11/09/06 - 20060251644 - High affinity anti-human ige antibodies The invention relates to high affinity human monoclonal antibodies, particularly those directed against isotypic determinants of immunoglobulin E (IgE), as well as direct equivalents and derivatives of these antibodies. These antibodies bind to their respective target with an affinity at least 100 fold greater than the original parent antibody. These ... 11/02/06 - 20060246056 - Immunotherapy of rectal cancer Described is the use of an immunotherapeutic agent targeting a human tumor associated antigen for the production of a medicament for immunotherapy of patients with rectal cancer or being at risk of rectal cancer, wherein the immunotherapeutic agent is a vaccine, an antibody or derivative or fragment thereof. ... 10/26/06 - 20060240000 - Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound Pharmaceutical composition comprising an anti-IgE antibody and at least one further antiallergic compound selected from the group consisting of anti-inflammatory agents, leukotriene modifiers, bronchodilators, antihistamines, interleukin antagonists, mast cell inhibitors, and immunotherapeutical agents, such as 33-epichloro,33-desoxyzascomycin (pimecrolimus), in which the active ingredients are present in each case in free form ... 10/26/06 - 20060239999 - Preventive and/or therapeutic drugs for asthma (wherein W represents CH or a nitrogen atom; Z1 and Z2 are the same or different and each represents hydrogen, a substituted or unsubstituted lower alkyl, or the like; and Z3 represents hydrogen, a substituted or unsubstituted lower alkyl, or the like)] as an active ingredient. ... 10/26/06 - 20060239998 - Anti-idiotypic antibodies against factor viii inhibitor and uses thereof The present invention discloses anti-idiotypic antibodies and fragments thereof against inhibitory Factor VIII anti-bodies, said inhibitory antibodies having an affinity for the C2 domain of Factor VIII. The anti-idiotypic antibodies of the present invention are able to completely neutralise in vitro and in an in vivo mouse model the inhibitory ... 10/19/06 - 20060233787 - Human cd3-specific antibody with immunosuppressive properties Described are mono- and multivalent scFv-antibodies comprising the binding sites specific for human T cell marker CD3. These antibodies are strongly immunosuppressive and do not cause a significant release of cytokines. Furthermore, polynucleotides encoding said antibodies are described as well as vectors comprising said polynucleotides, host cells transformed therewith and ... 09/14/06 - 20060204492 - Compositions and methods for producing enhanced antibodies The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity to αcβ3. The Vitaxin antibody consists of at least one Vitaxin heavy chain polypeptide and at least one Vitaxin light chain polypeptide or functional fragments thereof. Also provided are the Vitaxin heavy and light chain ... 07/27/06 - 20060165678 - Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof The present invention is directed to cell surface antigens found on myeloma cells and on ovarian cancer cells, and monoclonal antibodies, and antibody binding fragments thereof, capable of being used for therapeutic, diagnostic, detection and cell purification purposes. An exemplified monoclonal antibody of the present invention recognizes and binds to ... 07/27/06 - 20060165677 - Deletion forms of ige-dependent histamine releasing factor having histamine releasing activity, hrf-binding peptides and the uses thereof The present invention relates to IgE-dependent histamine releasing factor (HRF) and HRF-binding peptides, more precisely, deletion forms of HRF which are able to be formed as dimers containing amino acid sequence represented by SEQ ID NO:3, genes encoding thereof and novel HRF-binding peptides having an activity of inhibiting HRF. The ... 07/27/06 - 20060165676 - Identification of tsh receptor autoantibodies using affinity-purified antibodies The present invention relates to the use of affinity-purified polyclonal human autoantibodies against the TSH receptor (TSHR-Auto-Ab), obtained from the serum of Graves' disease patients and which have been purified to obtain biochemical homogeneity and comprise a specific activity of at least 1 IU/mg protein (human immunoglobulin). Also disclosed is ... 07/27/06 - 20060165675 - Modulation of mesenchymal cells via iga-receptors IgA receptors, including a polymeric immunoglobulin receptor (pIgR) and a FcαR, have been found on smooth muscle cells, synovial fibroblast cells and on both synovial and endothelial cells in synovial tissues from patients with arthritis. Incubation of smooth muscle cells or tissue with pIgA increases cytosolic calcium and alters the ... 07/20/06 - 20060159672 - Identification of self and non-self antigens implicated in autoimmune diseases The present invention provides isolated peptides relating to the autoimmune disease Pemphigus vulgaris. The peptides relating to Pemphigus vulgaris are self epitopes derived from human pathogens which are implicated in the aetiology and remissions of the disease. Pharmaceutical preparations for tolerizing and/or immunizing individuals are provided as well as methods ... 07/13/06 - 20060153832 - Immunomodulating polymers Methods and products for inducing IL-2 secretion, inducing IL-10 secretion, activating T cells, suppressing IgG antibody response to specific antigen, promoting allograft survival, reducing postoperative surgical adhesion formation, and protecting against abscess formation associated with surgery, trauma or diseases that predispose the host to abscess formation are provided. The methods ... 06/29/06 - 20060140930 - Promotion of central nervous system remyelination using monoclonal autoantibodies Monoclonal IgM antibodies which promote central nervous system remyelination when given to a mammal afflicted with a demyelinating disease are disclosed. These antibodies show multi-organ autoreactivity, and recognize both surface and cytoplasmic determinants on glial cells. ... 06/01/06 - 20060115471 - Treatment of disease with antibodies against high molecular weight kininogen domain 5 Antibodies directed against an antigenic determinant of high molecular weight kininogen domain 5, particularly a determinant located in the region formed by light chain amino acids Gly(440) to Lys(502), inhibit angiogenesis. ... 06/01/06 - 20060115470 - Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method ... 05/11/06 - 20060099201 - Treating a mammal with a formulation comprising an antibody which binds ige A method of treating a mammal with a formulation comprising an antibody which binds IgE as described. ... 04/06/06 - 20060073139 - Vaccine composition for preventing meningococcal disease The present invention relates to an anti-idiotype antibodies directed against the monoclonal antibody (HmenB3) to Neisseria meningitidis serogroup B and hybridomas producing the anti-idiotype antibodies. This invention is also directed to vaccine compositions comprising the anti-idiotypic antibodies in combination with pharmaccutically acceptable carriers. These vaccine compositions can be used to ... 03/23/06 - 20060062782 - Anti-ige vaccines The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of an IgE molecule as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions, methods for the treatment and prevention ... 03/23/06 - 20060062781 - Specific ab1'-antibodies against tumour-associated antigen ca 125 The present invention concerns specific anti-anti-idiotypic antibodies which react with anti-idiotypic antibodies which represent an internal image of the antigen CA125 and which also bind to the antigen itself i.e. are specific for the tumour-associated antigen CA125. In particular the present invention concerns a CA125-specific anti-anti-idiotypic antibody which reacts with ... 03/23/06 - 20060062780 - De-immunized (poly)peptide constructs The present invention relates to a (poly)peptide construct consisting of at least two domains of at least two pluralities of domains wherein one of said domains or pluralities of domains comprises a de-immunized autoreactive antigen or (a) fragment(s) thereof specifically recognized by the Ig receptors of an autoreactive B-cells and ... 03/16/06 - 20060057136 - Immunotherapy of b-cell malignancies using anti-cd22 antibodies B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. ... 02/02/06 - 20060024295 - Method for treating lupus A method of treating lupus in a subject eligible for treatment is provided involving administering an effective amount of an antibody that binds to a B-cell surface marker to the subject to provide an initial exposure and a subsequent exposure to the antibody within certain dosing regimens and an article ... 12/08/05 - 20050271651 - Inhibition of bright function as a treatment for excessive immunoglobulin production The present invention involves the identification of Bright as involved in immunoglobulin production, and the targeting of that function for the treatment of disease states associated with pathologic immunoglobulin production. Also provided are methods of identifying candidate substances with Bright-inhibitory activity. ... 11/10/05 - 20050249722 - Monoclonal antibodies with enhanced adcc function The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease ... 10/06/05 - 20050220785 - Methods and formulations for reducing circulating antibodies The invention provides methods for reducing circulating levels of antibodies, particularly disease-associated antibodies. The methods entail administering effective amounts of epitope-presenting carriers to an individual. In other embodiments, ex vivo methods for reducing circulating levels of antibodies are provided which employ epitope-presenting carriers. ... 09/01/05 - 20050191290 - Means and methods for manipulating hypersensitivity-like responses Immunoglobulin light chains (Ig-LC) are produced in excess in animals compared to heavy chains. The present invention implicates Ig-LC in hypersensitivity responses and provides ways for manipulating the responses. The invention further provides a common gamma chain-independent receptor on mast cells capable of mediating the mentioned effects of Ig-LC. In ... 08/25/05 - 20050186201 - Peptides immunoreactive with autoantibodies from patients suffering from rheumatoid arthritis The invention relates to a peptide derived from an antigen recognized by autoantibodies, which peptide is reactive with autoimmune antibodies from a patient suffering from rheumatoid arthritis. The peptide according to the invention possesses a modified arginine residue. The invention also relates to antibodies against the peptide and a method ... 08/11/05 - 20050175603 - Reduced-viscosity concentrated protein formulations The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations. ... 08/04/05 - 20050169914 - Novel functions for decay accelerating factor (daf) in inflammation The invention involves methods and products for interfering with neutrophil transmigration and treating inflammatory conditions. Agents that bind decay accelerating factor (DAF) and agents that mimic SCR-3 epitope of DAF are provided. ... 07/28/05 - 20050163768 - Monoclonal antibodies and their use Monoclonal murine internal image anti-idiotypic antibodies (Ab2) to monoclonal antibodies BR55-2 (Ab1), process for the production thereof and use for prophylactic and/or therapeutic immunization against HIV-infections, against cancer of epithelial origin and against small cell lung cancer. ... 07/21/05 - 20050158303 - Methods of treating ige-mediated disorders comprising the administration of high concentration anti-ige antibody formulations The present application relates to methods of treating IgE-mediated disorders comprising the administration of highly concentrated anti-IgE antibody formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. ... 07/21/05 - 20050158302 - Methods for diagnosing and treating autoimmune disease The invention provides a method of activating NFκB activity in a mammal afflicted with an autoimmune disease in which a reduction in NFκB activity is observed, comprising administering to a mammal suffering from the autoimmune disease a therapeutically effective amount of a polypeptide which activates NFκB, so as to treat ... 07/14/05 - 20050152893 - Methods and materials for the inhibition of transplant rejection The present invention provides compositions and methods of inhibiting transplant rejection in a mammal, comprising administering one or more transplant rejection inhibiting compounds to the mammal, wherein at least one compound includes an antibody that immunoreacts with the extracellular domain of the SPEX polypeptide. The present invention also provides a ... 07/07/05 - 20050147603 - Autoantibodies utilized as carrier agents for pharmaceutical compounds used in tumor imaging and cancer treatment This invention describes a method whereby human autoimmune antibodies are used as carrier compounds to deliver imaging agents and pharmaceutical drugs to the tumor in the human patient. These autoantibodies have the propensity to localize in necrotic areas of tumors but not in healthy normal tissues. By combining various pharmaceutical ... 06/09/05 - 20050123535 - Novel amino acid sequences, dna encoding the amino acid sequences, antibodies directed against such sequences and the different uses thereof B-cell epitope peptides of HSP 65, particularly the peptides comprising the amino acid sequence substantially as denoted by SEQ ID: Nos. 1-5 and their biologically functional homologues and derivatives thereof. Also included are polyclonal and monoclonal antibodies directed against them and their compositions for passive immunization against inflammatory and autoimmune ... ### FreshPatents.com Support |